Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 1, 2011

Primary Completion Date

June 20, 2016

Study Completion Date

January 20, 2019

Conditions
Breast Cancer
Interventions
RADIATION

Trastuzumab

Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks

Trial Locations (8)

10032

Columbia University, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

60611

Northwestern University, Chicago

78705

Texas Oncology-Austin, Austin

94143-1710

University of California San Francisco (UCSF), San Francisco

02111

Tufts Medical Center, Boston

02215

Dana Farber Cancer Institute, Boston

02903

Rhode Island Hospital, Providence

All Listed Sponsors
lead

Northwestern University

OTHER

NCT01325207 - Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer | Biotech Hunter | Biotech Hunter